Omer Kucuk is an Oncology physician affiliated with Emory University. OpenAlex indexes 315 publications with 10,171 citations (h-index 55); ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1365 Clifton Rd NE
Atlanta, GA 303221013
Telephone
405-778-5903Registry record last updated 27 Aug 2008.
Clinical trials
- Comprehensive Yoga Program (SKY) as Adjunct Therapy for Prostate Cancer
Sponsor: Emory University
- Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment
Sponsor: Emory University
- Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer
Sponsor: Barbara Ann Karmanos Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year20254 payments
- Exelixis Inc.Program year20241 payment
- Tempus AI, IncProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
69.4%Androgen Receptor Inhibitor42.6%Bicalutamide65%Xtandi35%Part D≥115 patientsCytochrome P450 17A1 Inhibitor14.9%Abiraterone Acetate100%Part D≥35 patients+ 3 more classes in this area
Metabolism & gastrointestinal
18.6%Corticosteroid16.2%Prednisone100%Part D≥46 patientsSerotonin-3 Receptor Antagonist1.3%Ondansetron Hcl100%Part D≥12 patients+ 1 more class in this area
Nervous system
8.3%Phenothiazine3.4%Prochlorperazine Maleate100%Part D≥32 patientsOpioid Agonist2.2%Oxycodone-Acetaminophen57%Oxycodone Hcl43%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells
Nature Communications
2022 - IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
Journal for ImmunoTherapy of Cancer
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Guyton, MD
Emory University
Keith Delman, MD
Emory University
Paolo Raggi, MD
Emory University
Monica Farley, MD
Emory University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”